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Abstract 
 
Background: Although lung transplantation from donation after cardiac death (DCD), especially 
uncontrolled DCD, is limited by warm ischemic periods, the molecular mechanism of warm 
ischemia-reperfusion-injury (IRI) has not been well elucidated. The purpose of this study was to 
clarify the particular longitudinal mechanisms of molecular factors involved in warm IRI. 
Methods: Cold ischemic-time (CIT)-group lungs were retrieved and subjected to 3-h of cold 
preservation, whereas warm ischemic-time (WIT)-group lungs were retrieved after 3-h of warm 
ischemia. Orthotopic rat lung transplantation was performed and the grafts were reperfused for 1 
or 4-h. The graft functions, gene expression, and activation of inflammatory molecules in the 
grafts were analyzed. Exhaled-carbon-monoxide-concentration (ExCO-C) was measured during 
reperfusion. 
Results: Only the WIT-group showed obvious primary graft dysfunction at 1-h reperfusion, but 
the graft function was recovered during 4-h reperfusion. Most of pro-inflammatory cytokines 
and stress-induced molecules showed different expression and activation patterns between CIT 
and WIT groups. In the WIT-group, the expressions of anti-inflammatory molecules, IL-10 and 
HO-1, were significantly increased at 1-h reperfusion compared to the CIT-group, and these 
high levels were maintained through 4-h reperfusion. Furthermore, ExCO-C levels in the 
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WIT-group increased immediately after reperfusion compared to the CIT-group. 
Conclusions: This study indicates that warm IRI may involve a different mechanism than cold 
IRI and anti-inflammatory pathways may play important roles in the graft recovery after lung 
transplantation from uncontrolled DCD. 
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1. Introduction 
 
Lung transplantation has become an accepted clinical option for patients with end-stage 
pulmonary diseases (1). However, the shortage of brain-dead donors remains a serious problem 
and the annual death rate for patients on lung transplant waiting lists varies from 13 to 30% (1, 
2). Using lungs from donation after cardiac death (DCD) might be a useful method to increase 
the donor pool, and the clinical application of uncontrolled DCD has recently been put to 
practical use (3-5).  
Ischemia-reperfusion injury (IRI) in lung transplantation leads to severe primary graft 
dysfunction (PGD), which unfortunately progresses to early morbidity and mortality in 10–20% 
of recipients (6). Lungs from uncontrolled DCD are inevitably subjected to warm ischemia, 
and the warm ischemic tolerance time is limited compared to cold ischemia (7-10). Therefore, 
IRI after warm ischemia is the most obstructive issue for progress with tentative transplantation 
of lungs from uncontrolled DCD. However, the graft functions of DCD have only recently been 
discussed, and the mechanism of warm IRI has not been well studied.  
 
2. Objective 
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The aim of this study was to demonstrate specific longitudinal changes in primary graft 
function and inflammatory molecule expression levels induced by warm IRI. To clarify the 
characteristics of warm IRI, it was necessary to explore the differences between cold and warm 
IRI using the orthotopic vascularized lung transplant model.  
 
3. Materials and Methods 
 
3.1. Lung transplantation 
Male Sprague-Dawley rats (Charles River, Yokohama, Japan) weighing 250–300 g were used 
for the experiments. The orthotopic single left lung transplantation was performed as previously 
reported using the cuff technique (11, 12). The donor rat was anesthetized by inhalation of 
diethyl ether following intraperitoneal injection of pentobarbital sodium (60 mg/kg). After 
tracheotomy, the rat was ventilated with a mixture of halothane and oxygen to maintain 
anesthesia, heparinized by the intrahepatical injection of 600 IU/body heparin through a small 
laparotomy, and divided into 1 of 2 groups (Figure 1). In the cold ischemic-time (CIT) group, a 
median laparosternotomy was performed and the donor lung was retrieved after flushing with 
low-potassium dextran glucose (LPDG) solution. The graft underwent cold (4°C) preservation 
for 3-h. In the warm ischemic-time (WIT) group, the donor lung underwent 3-h of warm 
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ischemia. In brief, the donor was exsanguinated by cutting the inferior vena cava through a 
small laparotomy and immediately put to death. The tracheal tube was disconnected and the 
cadaver was stored in a chamber at room temperature (28°C). After 3-h warm ischemic period, a 
median laparosternotomy was performed and the lung was retrieved after flushing with LPDG 
solution. In both CIT and WIT groups, the total ischemic-time including the time of 
transplantation was 4-h. The recipient was anesthetized and a left thoracotomy was performed. 
The pulmonary vessels and bronchus were anastomosed with standard cuff technique. After 
reperfusion, the recipient was kept anesthetized with a mixture of 0.5% halothane and oxygen 
under ventilation and sacrificed at 1-h (-1hRe) or 4-h (-4hRe) after reperfusion (n = 5 each). In 
the sham group, the rats underwent only anesthesia and thoracotomy (n = 5).  
 
3.2. Blood gas analysis 
The right hilum was clamped for 5-min after changing the tidal volume and respiratory rate 
ventilator settings to 0.6 ml/100g and 100 breaths/min, respectively. The arterial blood sample 
was taken from the ascending aorta to analyze the blood gas on a FiO2 1.0. Finally, the graft 
lung was removed and separated into 3 blocks (upper, middle and lower) and stored at -80°C. 
 
3.3. Histology and neutrophil infiltrations 
 Middle part of the horizontal section of donor lung was fixed in 10% formalin and stained with 
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Haematoxylin-Eosin (H&E). Under high power magnification (HPF; X200), five fields from central 
to peripheral parts on one slice were accurately sampling with equal probability of each graft lung 
and neutrophils were identified and counted for two slices in a blinded fashion by a pathologist. The 
average numbers of neutrophils/HPF were used for SEM.  
 
3.4. Western blot analysis 
The lower specimen was homogenized on ice using an ultrasonic processor in 1 X lysis buffer 
(RIPA buffer; Cell Signaling, Beverly, MA) containing a cocktail of protease inhibitors 
(Complete Mini; Roche, Indianapolis, IN). Equal amounts of each protein sample (50 µg) were 
loaded on sodium dodecyl sulfate (SDS)-polyacrylamide gels and electroblotted to a 
polyvinylidene difluoride (PVDF) transfer membrane. The membranes were incubated 
overnight at 4°C using a primary antibody against phospho-p38 mitogen-activated protein 
kinase (MAPK) (Bio Vision, Mountain View, CA). The site of primary antibody binding was 
visualized with horseradish peroxidase-conjugated rabbit antibody (Santa Cruz Biotechnology, 
Santa Cruz, CA) followed by the detection step and exposure to film. The same membrane was 
rinsed and re-blotted with a primary antibody against total–p38 (Delta Biolabs, Gilroy, CA) and 
the same detection and exposure to film processes were repeated. The image was analyzed by 
densitometry (Image J software version 1.2; Media Cybernetics, Silver Spring, MD) to assess 
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the relative level of p38 activation in the different groups by calculating the ratio of 
phospho-p38/total p38. 
 
3.5. Real-time RT-PCR technique 
The upper specimen was homogenized and RNA was isolated using TRIZOL Reagent 
(Invitrogen, Carlsbad, CA) following the manufacture’s protocol. DNA was removed using the 
DNA-free kit (TURBO DNA-free; Ambion, Austin, TX) following the manufacturer’s protocol. 
Total RNA (2 µg) was used for reverse transcription (RT) using the SuperScriptTM III-RT Kit 
(Invitrogen, Carlsbad, CA) according to the manufacturer’s protocol. The resulting cDNA 
sample was diluted 1:20 and 1 µl was used for real-time RT-PCR.  
Real-time RT-PCR was performed using LightCycler technology (Roche Diagnostics, 
Mannheim, Germany) to quantify the expression of the following mRNAs: tumor necrosis 
factor-α (TNF-α), interleukin (IL)-1β, IL-6, IL-10, monocyte chemotactic protein-1 (MCP-1), 
macrophage inflammatory protein-2 (MIP-2), plasminogen activator inhibitor-1 (PAI-1), 
intercellular adhesion molecule-1 (ICAM-1), cyclooxygenase-2 (COX-2), heme oxygenase-1 
(HO-1), and β-actin. The forward and reverse primers and Taq probes were designed using 
Probe Finder software (https://www.roche-applied-science.com/sis/rtpcr/upl/index.jsp) from 
Roche Diagnostics. Each primer was designed to span 2 different exons. Real-time RT-PCR was 
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performed using the LightCycler TaqMan Master from Roche Diagnostics with each primer pair 
and taq probe following the manufacturer’s protocol. 
The second derivative maximum method was used to automatically estimate the crossing points 
for individual samples. The relative amount of target gene was calculated on the basis of the 
cross-point analysis (LightCycler software version 3.5; Roche Diagnostics, Mannheim, 
Germany) on an external standard curve created by blotting the log number of copies by using 
serial dilutions of 1 control sample. The relative data for experimental genes were normalized as 
a ratio to β-actin concentration and shown compared to the mean data of the sham group. 
 
3.6. Exhaled Carbon-monoxide (CO) measurement 
Exhaled-carbon-monoxide-concentration (ExCO-C) was analyzed using a CO analyzer 
(CarbolyzerTM mBA-2000; Taiyo Instruments Inc., Osaka, Japan). Another series of single left 
lung transplantation followed by 4-h of reperfusion were performed as described above in each 
group (n = 5 each). A sampling adaptor was side attached to the ventilator circuit for collecting 
the exhaled air, and the ExCO-C was measured during the 4-h reperfusion at 13 time points: 0, 
15, 30, 45, 60, 75, 90, 105, 120, 150, 180, 210, and 240 min. The mean ExCO-C for 1 min was 
calculated by the special software package (CarbolyzerTM Data BOX; Taiyo Instruments Inc.) 
at each time point. The excretion change level of ExCO-C at each time point was calculated 
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from the ExCO-C level using the starting point as a base level. 
 
3.7. Statistical analysis 
All values are presented as mean ± standard deviation (SD). The one-way repeated-measures 
analysis of variance (ANOVA) followed by Tukey-Kramer test for multiple comparisons were 
used to compare the levels of phospho-p38, mRNA levels, and ExCO-C between groups. 
Probability values less than 0.05 were regarded as statistically significant for all tests. All 
analyses were performed using Stat View 5.0 Program for Windows (SAS Institute Inc., Cary, 
NC). 
 
3.8. Animal Care 
The Animal Care Committee at Okayama University approved the protocol for this study. All 
rats received humane care in compliance with The Principles of Laboratory Animal Care 
formulated by the National Society for Medical Research and the Guide for the Care and Use of 
Laboratory Animals (NIH Publication No.86-23, 1996). 
 
4. Results 
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4.1. Pulmonary Graft Function 
The PaO2 level of the WIT-1hRe group was significantly lower than those of the CIT-1hRe and 
sham groups (p < 0.01), although the PaO2 of the CIT-1hRe was the same as that of the sham 
group (Figure 2 A). However, the PaO2 of the WIT-4hRe group was significantly higher than 
that of the WIT-1hRe group (p < 0.01), indicating that the pulmonary function of the graft 
subjected to 3-h of warm ischemia recovered during the 4-h reperfusion period. The recovery of 
pulmonary function was clear and the WIT-4hRe group showed comparable oxygenation 
relative to the sham and CIT-4hRe groups. Histological examination showed alveolar oedema 
only in WIT-1hRe group (Figure 2 B). All groups showed significant neutrophil infiltrations 
compared to sham group (p < 0.01). A significant increase of neutrophils was observed in 
WIT-1hRe group, whereas they were significantly decreased in WIT-4hRe group (p < 0.01) 
(Figure 2 C).  
 
4.2. Pro-inflammatory cytokines and stress-induced molecules 
The expression levels of all pro-inflammatory molecules were significantly increased in the 
WIT-1hRe group than the sham group (p < 0.01) (Figure 3), and the expression levels of IL-1β, 
IL-6, MCP-1, ICAM-1, and COX2 were significantly higher in the WIT-1hRe group 
compared to the CIT-1hRe group (p < 0.01). However, these significant differences were no 
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longer observed at 4-h reperfusion between CIT and WIT groups with the exception of IL-6. 
TNF-α and MIP-2 expression levels were not significantly different between the CIT and WIT 
groups at 1-h or 4-h reperfusion, although MIP-2 expression levels were significantly decreased 
after 4-h reperfusion in both groups (p < 0.01). The expression of PAI-1, comparable between 
the CIT-1hRe and WIT-1hRe groups, decreased in the CIT-4hRe group and was significantly 
lower than that of the WIT-4hRe group (p < 0.01).  
 
4.3. Anti-inflammatory cytokine and molecules 
IL-10 gene expression was significantly increased in the WIT-1hRe group than the sham group, 
and this high expression level was maintained at 4-h reperfusion (Figure 4A). In the CIT-1hRe 
group, the IL-10 expression levels were significantly lower than those in the WIT-1hRe group (p 
< 0.01) and were up-regulated only at 4-h reperfusion. The gene expression patterns of HO-1 
and IL-10 were the same (Figure 4A). P38 was activated only at 4-h reperfusion in the CIT 
group, whereas the WIT group showed significant activation of p38 at 1-h reperfusion (Figure 
4B), and this activation was maintained until 4-h reperfusion. P38 activation showed the same 
pattern as the mRNA expression levels of IL-10 and HO-1. 
 
4.4. Exhaled CO measurement 
13 
 
Changes in ExCO-C during the 4-h reperfusion are indicated in Figure 4C. In the CIT group, the 
ExCO-C started to increase approximately 120-min after reperfusion and slightly increased until 
240-min after reperfusion. On the other hand, the ExCO-C in the WIT group was rapidly 
elevated after reperfusion, and these levels were significantly higher than CIT group from 60 to 
105-min after reperfusion. The ExCO-C gradually increased in the WIT group from 105-min 
until 240-min after reperfusion and was also significantly different from the CIT group from 
180 to 240-min (60, 75, 90, 105, 180, 210, and 240 min: p < 0.05). 
  
5. Discussion 
 
IRI after lung transplantation is thought to be a biphasic process (13, 14).  The initial 
phase of injury occurs within the first 30 minutes of reperfusion, and mainly depends on 
donor characteristics of endothelial cells and alveolar macrophages(15). Endothelial cell 
is known to contribute to PGD by its inductions of powerful vasoconstrictors and 
vascular hyper permeability factors, like endothelin-1 and vascular endothelial growth 
factor(16). Moreover, activated resident alveolar macrophages in donor lung are also 
known to mediate early phase of IRI by its productions of several proinflammatory 
cytokines and chemokines(15, 17). These mediators result in the recruitment and activation of 
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recipient neutrophils to the transplanted lung, eliciting a subsequent late phase of injury that 
generally occurs 4 to 6 hours after reperfusion. Activated neutrophils produce a number of 
proteolytic enzymes and reactive oxygen species (ROS) that produce end-organ damage in the 
allograft. Most of rodent models of lung cold IRI demonstrated that the late phase of injury 
show worse graft function than the initial phase of injury (18, 19). In this study, DCD lungs 
were subjected to warm ischemia in the closed cadaver thoracic cavity similar to a clinical 
situation of uncontrolled DCD (Maastricht classification Category I NHBD) and transplanted 
orthotopically. In contrast to cold IRI models, the pulmonary graft function and neutrophil 
infiltrations of uncontrolled DCD group improved after 4-h reperfusion in the recipient body. 
Recent clinical reports also indicated that DCD lung grafts could recover from the first PGD 
within 6-h after reperfusion (20, 21). Furthermore, our group showed the recovery potential of 
DCD lung grafts while reperfusion and it started within 1-h after reperfusion by using swine 
model as well (22). These findings suggest that uncontrolled DCD lung may possess good 
recovery potential and warm IRI may involve a different mechanism than cold IRI.  
We analyzed the differences of longitudinal changes in gene expression levels of inflammatory 
cytokines and molecules between cold and warm IRI. In cold IRI, proinflammatory cytokines 
such as TNF-α, IL-1β, IL-6, and COX2 and chemokines such as MIP-2 and MCP-1 (23, 24) 
have been identified as molecular factors that regulate IRI in lung transplants (25-28). In 
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addition, PAI-1 and ICAM-1 are proinflammatory molecules (29, 30) that reportedly lead to IRI 
by fibrin deposit and cell adhesion in rat lung transplantation and mouse IRI models (25-27). 
In the present study, all proinflammatory mediators were upregulated by warm IRI, although 
IL-1β, COX2, and ICAM-1 were not increased by cold IRI as previously reported (15, 31). 
Significant differences in the gene expression levels of IL-1β, IL-6, MCP-1, COX2, and 
ICAM-1 were observed at 1-h reperfusion between cold and warm IRI, and these differences 
were correlated with blood gas oxygenation. However, the expressions of most of these genes in 
the warm IRI group had decreased to comparable levels of the cold IRI group during 4-h after 
reperfusion. The reduction of these proinflammatory cytokines after warm IRI was consistent 
with improvement of pulmonary function. On the other hand, TNF-α and MIP-2 were also 
upregulated by cold IRI, but the expression levels were comparable to warm IRI at both 1 h and 
4 h after reperfusion. Thus, proinflammatory cytokines showed different and various expression 
patterns between cold and warm IRI, suggesting that both the degree of injury and the 
mechanism may be different in cold and warm IRI. 
Anti-inflammatory molecules were also examined as we considered them to play an important 
role in the recovery process of DCD lungs, because they have been shown to reduce IRI and 
their inhibition promotes lung injury (32-36). IL-10 is a pleiotropic cytokine that mainly 
functions to limit and terminate inflammatory responses, and exogenous IL-10 has been shown 
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to prevent lung IRI in several studies (35-38). HO-1 is also induced by a variety of 
oxidant/inflammation stresses, plays an important role in the cytoprotective response (32, 33), 
and reduces IRI by producing CO, biliverdin, and bilirubin (34, 39-43). In the current study, the 
differences between cold and warm IRI in the expressions and activations of anti-inflammatory 
pathways were more obvious than those of pro-inflammatory molecules. IL-10 and HO-1 
displayed different expression patterns in the grafts that underwent warm IRI compared to cold 
IRI. After cold IRI, the expression levels of IL-10 and HO-1 gradually increased over the 
reperfusion period. On the other hand, IL-10 and HO-1 expression levels were significantly 
higher at 1-h reperfusion after warm ischemia when the graft showed severe PGD. IL-10 and 
HO-1 were still highly expressed 4-h after warm IRI, while the graft recovered from IRI. These 
results suggest that these anti-inflammatory mediators are expressed early after warm IRI and 
may play a pivotal role in graft recovery. Several reports have demonstrated that IL-10 induces 
the expression of HO-1 via p38 activation and the anti-inflammatory molecules are thought to 
be further amplified by their own mutual positive-feedback circuit (44, 45). We observed a 
similar association between activated p38 and IL-10 and HO-1 expression in this study, and this 
indicated that the anti-inflammatory signaling pathway from IL-10 to HO-1 through p38 
activation was rapidly induced in the graft after warm IRI to heal the severe injury associated 
with ischemic conditions.  
17 
 
We measured ExCO-C to further study the anti-inflammatory system after warm IRI. CO, a 
product of heme breakdown mediated by HO-1, diffuses out of cells, enters the bloodstream to 
form carboxyhemoglobin, and is transported to the lungs for excretion (46). Previous studies 
reported that ExCO-C was increased in inflammatory airway diseases, systemic inflammatory 
diseases like sepsis and critical illness, and in IRI of living donor liver transplantation (47, 48). 
Recently, Vos et al. demonstrated the correlation between ExCO-C and airway neutrophilia after 
lung transplantation, and it could be used as a noninvasive marker for airway inflammation (49). 
On the other hand, a low exogenous dose of CO has been shown to reduce IRI in the lung and 
other solid organ transplantation models (28, 42, 50-52), and even in cerebral (53) and 
myocardial (54) infarction models. Consistent with HO-1 expression, ExCO-C was rapidly 
elevated after warm IRI following reperfusion but not after cold IRI. This finding suggests that 
CO may have a protective effect on the graft and reduce IRI after warm IRI and also supports 
the importance of the anti-inflammatory process in graft recovery.  
Warnecke et al. reviewed the differences between cold and warm IRI and commented that there 
are no major differences on lung functions (55). However, the current study demonstrated that 
differences may exist in the processes and changes associated with cold and warm IRI. This 
study also suggested that anti-inflammatory molecules such as IL-10, HO-1, and CO are rapidly 
induced after warm IRI and may have potential to recover the graft against warm IRI. In case of 
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lung retrieval, ex-vivo treatment, and medication for the recipient after lung transplantation 
form uncontrolled DCD, specific strategy by utilizing these molecules may be effective for the 
reduction of IRI. However, further studies are required to substantiate these findings by 
suppression or overexpression of inflammatory and anti-inflammatory molecules using 
inhibitors or knockout mice lung transplantation models.  
Although this study may have shown the differences after reperfusion, the differences during 
cold and warm ischemia have to be considered as well. During ischemia, macrophage and 
endothelial cells have been shown to induce cytokines and ROS(15, 17), but cytokines 
have been shown little up-regulations while both cold and warm ischemic period(56, 57). 
The current study also showed rapid cytokine up-regulation only after reperfusion with 
little expression while ischemic period in preliminary experiments (data not shown). 
Metabolism and cell death during ischemia may also contribute to the differences 
between cold and warm IRI. While hypothermia decreases metabolic rate, warm 
ischemia leads a sharp decrease of adenosine triphosphate (ATP) and then generates 
ROS(15, 17, 58). Apoptosis is not present during ischemia but after reperfusion, and 
does not correlate with pulmonary function(59). However, 2-h of warm ischemia has 
been shown to cause 36% of cell necrosis and necrotic cells release intracellular proteins 
just after reperfusion(60). The rapid inflammatory change after warm ischemia in our 
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study may have been caused by these proteins released from necrotic cells right after 
reperfusion. However, it is difficult to reveal the mechanisms during ischemia to cause 
the differences between cold and warm ischemia from our results, and further 
experiments targeting metabolic rate and cell death may be necessary to clarify the 
mechanisms.  
In summary, this novel report delineated the differences between cold and warm 
ischemia-reperfusion at the molecular level by using the orthotopic rat lung transplantation 
model. Furthermore, anti-inflammatory molecules may play important roles in the graft 
recovery after warm IR. These findings have possibilities to lead to novel therapies against IRI 
after lung transplantation from uncontrolled DCD to increase the potential donor pool. 
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Figure legends 
 
Fig. 1 
Schematic overview of the rat lung transplant experiment. All donor rats were heparinized and 
followed by sudden cardiac arrest by the protocol described in the text. All donor lungs were 
flushed with LPDG solution before the harvest. The donor lung for cold ischemia (CIT) was 
preserved at 4°C after lung retrieval and the lung of uncontrolled DCD (WIT) was kept in a 
cadaver at 28°C for 3 h before lung retrieval. In both groups, orthotopic vascularized single left 
lung transplantation was performed and the graft was reperfused after 4 h of total ischemic time. 
The grafts were assessed at 1 and 4 h after reperfusion (n = 5 in each group).  
 
Fig. 2 
Pulmonary graft functions after cold and warm ischemia-reperfusion. (A)  Arterial oxygenation 
(PaO2) was determined with isolated lung graft circulation and ventilation on a FiO2 1.0 (n = 5 
in each group). Data are expressed as means ± SD. PaO2 levels of the WIT group were 
significantly worse than the sham and CIT groups after 1h reperfusion (*p < 0.05; vs. sham, ‡p 
< 0.05; vs. CIT at the same reperfusion time). The PaO2 level of the WIT group at 4-h 
reperfusion was markedly improved compared to 1-h reperfusion (†p < 0.05; 1 h vs. 4 h after 
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reperfusion in each group), and there were no significant differences when compared to the 
sham and CIT group after 4 h of reperfusion. 
(B) Representative histologic analysis (n = 5) of lung grafts from sham operations (a), 1-h and 
4-h reperfusion after cold ischemia (b, c) and 1-h and 4-h reperfusion after warm ischemia (d, e). 
Lung grafts were stained with hematoxylin-eosin. (X200 magnification) 
(C) The total neutrophil counts per one HPF are shown as a mean ± SD (*p < 0.05). Neutrophils 
were significantly infiltrated into graft lung after ischemia-reperfusion (*p < 0.05; vs. Sham). 
The intragraft neutrophil numbers after 4-h reperfusion were markedly decreased compared to 
1-h reperfusion after warm ischemia (
†
p < 0.05). 
 
Figure 3 
Intragraft mRNA expression levels of proinflammatory cytokines and stress-induced molecules 
after ischemia-reperfusion. The expression level of mRNA was quantified using real-time 
RT-PCR and is shown relative to the β-actin housekeeping gene mRNA level. The relative 
mRNA level of each group (n = 5) was compared to the sham group (n = 5), and the fold data 
are expressed as means ± SD. (*p < 0.05; vs. sham, ‡p < 0.05; CIT vs. WIT at the same 
reperfusion time, †p < 0.05; 1 h vs. 4 h after reperfusion in each group).  
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Figure 4 
Longitudinal changes of anti-inflammatory factors induced by cold and warm 
ischemia-reperfusion injury. Data are expressed as means ± SD. (A) mRNA expression levels of 
IL-10 and HO-1 were quantified using real-time RT-PCR and are shown relative to the β-actin 
housekeeping gene mRNA expression level. The relative mRNA fold level of each group (n = 5) 
is expressed compared to the sham group (n = 5). (‡p < 0.05; CIT vs. WIT at the same 
reperfusion time, †p < 0.05; 1 h vs. 4 h after reperfusion in each group). (B) Levels of 
phosphorylated-p38 (phospho-p38) in isolated lung grafts (n = 5) at 1 and 4 h of reperfusion 
after cold and warm ischemia were evaluated by western blot analysis. A representative image 
of 5 independent experiments is shown. Band intensity was quantified and expressed as the ratio 
of phospho-p38 to total-p38. (‡p < 0.05; CIT vs. WIT at the same reperfusion time, †p < 0.05; 1 
h vs. 4 h after reperfusion in each group). (C) Changes in exhaled carbon monoxide 
concentrations (ExCO-C) during reperfusion after rat lung transplant. The ExCO-C of the 
recipient rat transplanted with the DCD lung gradually increased throughout the reperfusion 
period, but the ExCO-C from the recipient rat transplanted under CIT conditions showed an 
increased level from 120 min after the reperfusion time point. Significant differences between 
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CIT and WIT were identified at 60, 75, 90, 105, 210, and 240 min after reperfusion (§p < 0.05; 
CIT vs. WIT at the same reperfusion time)  
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